Evidence map›Paper›PMID 33996291›Full record

ArticleCureus2021

Discordant Immune Marker Expression Between Preoperatively Biopsied and Matched Surgically Resected Specimens in Patients With Oral Squamous Cell Carcinoma.

Masahiro Kikuchi, Daisuke Yamashita, Shigeo Hara, Shinji Takebayashi, Kiyomi Hamaguchi, Keisuke Mizuno, Koichi Omori, Shogo Shinohara

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Masahiro KikuchiOtolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, JPN.
Daisuke YamashitaDepartment of Pathology, Kobe City Medical Center General Hospital, Kobe, JPN.
Shigeo HaraDepartment of Pathology, Kobe City Medical Center General Hospital, Kobe, JPN.
Shinji TakebayashiDepartment of Otolaryngology, Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, JPN.
Kiyomi HamaguchiDepartment of Otolaryngology, Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, JPN.
Keisuke MizunoOtolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, JPN.
Koichi OmoriOtolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, JPN.
Shogo ShinoharaDepartment of Otolaryngology, Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe, JPN.
Kyoto University · JPKobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death ligand 1 (PD-L1) expression and tumor-associated immune cell (TAIC) density can be the biomarkers of survival outcome and for predicting the efficacy of immune checkpoint inhibitors in oral squamous cell carcinoma (OSCC), but whether single biopsy accurately reflects the values of these parameters in resected specimens is unclear. To clarify this, we evaluated the concordance of immune marker expression (PD-L1, PD-1, CD3, CD4, CD8, and CD68) between 39 paired biopsied and surgically resected specimens obtained from patients with OSCC at Kobe City Medical Center General Hospital between July 2011 and January 2016. Immune marker expression was assessed using immunohistochemistry. PD-L1 expression was consistent between the biopsied and surgically resected specimens in only 76.9% of cases. TAIC density was significantly lower in biopsied than in surgically resected specimens. There was considerable discordance in immune marker expression between biopsied and surgically resected specimens. We should take into consideration that PD-L1 positivity and TAIC density would be underestimated by single small biopsies compared to the estimations by surgically resected specimens.

Indexed as

immune markeroral squamous cell carcinomapd-l1tumor-associated immune cell

Identifiers

PMID33996291
PMCPMC8112876
OpenAlexW3156677398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.